Stem Cell Therapy for Acute Myocardial Infarction and Cardiomyopathy: The Emergency Medicine Perspective
Main Article Content
Abstract
Ischemic cardiovascular disease remains the leading cause of death worldwide. Patients with acute myocardial infarction and cardiomyopathy are commonly treated in the emergency department, with emphasis on pharmacologic stabilization, thrombolysis, and expeditious transfer to percutaneous coronary intervention and/or the inpatient cardiac unit. The nexus between emergency medicine and regenerative medicine, which focuses on repair and restoration of damaged tissue, is just beginning. The use of stem cells, which are capable of extensive proliferation and differentiation into myriad lineage cells, are a key component of regenerative medicine. Over the past two decades, stem cell research has expanded and demonstrated benefit in animal and human studies of acute myocardial infarction and cardiomyopathy. However, stem cell treatment must be initiated early to achieve the best outcome. Emergency physicians may soon be involved in this regenerative process, with procurement and administration of stem cells during the initial stabilization of the acute cardiac patient in the emergency department. In this article, we discuss the emergency medicine perspective on the selection of specific types of stem cells and their adjuncts, route, timing, mechanisms of healing, relevant clinical scenarios, and review the evidence and safety behind this futuristic treatment.
Article Details
How to Cite
RICHARDS, John R. et al.
Stem Cell Therapy for Acute Myocardial Infarction and Cardiomyopathy: The Emergency Medicine Perspective.
Medical Research Archives, [S.l.], v. 13, n. 9, sep. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6911>. Date accessed: 06 dec. 2025.
doi: https://doi.org/10.18103/mra.v13i9.6911.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Leading causes of death. Accessed July 15, 2025. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death
2. Premer C, Schulman IH, Jackson JS. The role of mesenchymal stem/stromal cells in the acute clinical setting. Am J Emerg Med. 2021;46:572-578. doi:10.1016/j.ajem.2020.11.035
3. Assmus B, Dimmeler S, Zeiher AM. Cardiac Cell Therapy. Circ Res. 2015;116(8):1291-1292. doi:10.1161/CIRCRESAHA.115.306330
4. Öztürk S, Elçin AE, Koca A, Elçin YM. Therapeutic Applications of Stem Cells and Extracellular Vesicles in Emergency Care: Futuristic Perspectives. Stem Cell Rev Rep. 2021;17(2):390-410. doi:10.1007/s12015-020-10029-2
5. Ali SA, Mahmood Z, Mubarak Z, et al. Assessing the Potential Benefits of Stem Cell Therapy in Cardiac Regeneration for Patients With Ischemic Heart Disease. Cureus. 2025;17(1):e76770. doi:10.7759/cureus.76770
6. Marbán E. Breakthroughs in Cell Therapy for Heart Disease: Focus on Cardiosphere-Derived Cells. Mayo Clin Proc. 2014;89(6):850-858. doi:10.1016/j.mayocp.2014.02.014
7. Chepeleva EV. Cell Therapy in the Treatment of Coronary Heart Disease. Int J Mol Sci. 2023;24(23):16844. doi:10.3390/ijms242316844
8. Skrypnyk M. Current progress and limitations of research regarding the therapeutic use of adipose-derived stem cells: literature review. J Umm Al-Qura Univ Appl Sci. 2025;11(1):63-75. doi:10.1007/s43994-024-00147-9
9. Rheault-Henry M, White I, Grover D, Atoui R. Stem cell therapy for heart failure: Medical breakthrough, or dead end? World J Stem Cells. 2021;13(4):236-259. doi:10.4252/wjsc.v13.i4.236
10. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step. Circulation. 2006;114(4):339-352. doi:10.1161/ circulationaha.105.590653
11. Chakravarti AR, Pacelli S, Alam P, et al. Pre-Conditioning Stem Cells in a Biomimetic Environment for Enhanced Cardiac Tissue Repair: In Vitro and In Vivo Analysis. Cell Mol Bioeng. 2018;11(5):321-336. doi:10.1007/s12195-018-0543-x
12. Xue T, Cho HC, Akar FG, et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation. 2005;111(1):11-20. doi:10.1161/01.CIR.0000151313.18547.A2
13. Menasché P, Vanneaux V, Hagège A, et al. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2018;71(4):429-438. doi:10.1016/j.jacc.2017.11.047
14. Menasché P, Vanneaux V, Hagège A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. 2015;36(30):2011-2017. doi:10.1093/eurheartj/ehv189
15. Dhar D, Hsi-En Ho J. Stem cell research policies around the world. Yale J Biol Med. 2009;82(3):113-115.
16. Lin Q, Fu Q, Zhang Y, et al. Tumourigenesis in the infarcted rat heart is eliminated through differentiation and enrichment of the transplanted embryonic stem cells. Eur J Heart Fail. 2010;12(11):1179-1185. doi:10.1093/eurjhf/hfq144
17. Brizard CP, Elwood NJ, Kowalski R, et al. Safety and feasibility of adjunct autologous cord blood stem cell therapy during the Norwood heart operation. J Thorac Cardiovasc Surg. 2023;166(6):1746-1755. doi:10.1016/j.jtcvs.2023.07.035
18. Ahmed MM, Meece LE, Handberg EM, et al. Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recipients: Results of the uSTOP LVAD BLEED pilot study. JHLT Open. 2024;3:100037. doi:10.1016/j.jhlto.2023. 100037
19. Troyer DL, Weiss ML. Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells Dayt Ohio. 2008;26(3):591-599. doi:10.1634/ stemcells.2007-0439
20. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013;14(6):11692-11712. doi:10.3390/ijms140611692
21. Gao LR, Chen Y, Zhang NK, et al. Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Med. 2015;13:162. doi:10.1186/s12916-015-0399-z
22. Roura S, Bagó JR, Soler-Botija C, et al. Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in vivo. PloS One. 2012;7(11):e49447. doi:10.1371/journal.pone.0049447
23. Lim M, Wang W, Liang L, et al. Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction. Stem Cell Res Ther. 2018;9(1):129. doi:10.1186/s13287-018-0888-z
24. Correa A, Ottoboni GS, Senegaglia AC, et al. Expanded CD133+ Cells from Human Umbilical Cord Blood Improved Heart Function in Rats after Severe Myocardial Infarction. Stem Cells Int. 2018;2018:5412478. doi:10.1155/2018/5412478
25. Liu C, Kang LN, Chen F, et al. Immediate Intracoronary Delivery of Human Umbilical Cord Mesenchymal Stem Cells Reduces Myocardial Injury by Regulating the Inflammatory Process Through Cell-Cell Contact with T Lymphocytes. Stem Cells Dev. 2020;29(20):1331-1345. doi:10.1089/scd.2019.0264
26. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872. doi:10.1016/j.cell.2007.11.019
27. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. doi:10.1016/j.cell.2006.07.024
28. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-1920. doi:10.1126/science.1151526
29. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104(4):e30-41. doi:10.1161/CIRCRESAHA.108.192237
30. Blin G, Nury D, Stefanovic S, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest. 2010;120(4):1125-1139. doi:10.1172/ JCI40120
31. Dixit P, Katare R. Challenges in identifying the best source of stem cells for cardiac regeneration therapy. Stem Cell Res Ther. 2015;6(1):26. doi:10.1186/s13287-015-0010-8
32. Ahmed RPH, Ashraf M, Buccini S, Shujia J, Haider HK. Cardiac tumorigenic potential of induced pluripotent stem cells in an immunocompetent host with myocardial infarction. Regen Med. 2011;6(2):171-178. doi:10.2217/rme.10.103
33. Rais Y, Zviran A, Geula S, et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature. 2013;502(7469):65-70. doi:10.1038/natur e12587
34. Kirkeby A, Main H, Carpenter M. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell. 2025;32(1):10-37. doi:10.1016/j.stem.2024.12.005
35. Ortuño-Costela MDC, Cerrada V, García-López M, Gallardo ME. The Challenge of Bringing iPSCs to the Patient. Int J Mol Sci. 2019;20(24):6305. doi:10.3390/ijms20246305
36. He JQ, Vu DM, Hunt G, Chugh A, Bhatnagar A, Bolli R. Human cardiac stem cells isolated from atrial appendages stably express c-kit. PloS One. 2011;6(11):e27719. doi:10.1371/journal.pone.0027719
37. Madigan M, Atoui R. Therapeutic Use of Stem Cells for Myocardial Infarction. Bioeng Basel Switz. 2018;5(2):28. doi:10.3390/bioengineering5020028
38. Moccetti T, Leri A, Goichberg P, Rota M, Anversa P. A Novel Class of Human Cardiac Stem Cells. Cardiol Rev. 2015;23(4):189-200. doi:10.1097/CRD.0000 000000000064
39. Samanta A, Dawn B. Meta-Analysis of Preclinical Data Reveals Efficacy of Cardiac Stem Cell Therapy for Heart Repair. Circ Res. 2016;118(8):1186-1188. doi:10.1161/CIRCRESAHA.116.308620
40. Makkar RR, Kereiakes DJ, Aguirre F, et al. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2020;41(36):3451-3458. doi:10.1093/eurheartj/ehaa541
41. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110-122. doi:10.1016/j.jacc.2013.08.724
42. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329-2338. doi:10.1016/j.jacc.2013.02.071
43. Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38(9):648-660. doi:10.1093/ eurheartj/ehw543
44. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313-12318. doi:10.1073/pnas.2132126100
45. Micheu MM, Dorobantu M. Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction. World J Stem Cells. 2017;9(4):68-76. doi:10.4252/wjsc.v9.i4.68
46. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98(18):10344-10349. doi:10.1073/pnas.181177898
47. Nigro P, Bassetti B, Cavallotti L, Catto V, Carbucicchio C, Pompilio G. Cell therapy for heart disease after 15 years: Unmet expectations. Pharmacol Res. 2018;127:77-91. doi:10.1016/j. phrs.2017.02.015
48. Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009-3017. doi:10.1161/01.cir.0000043246.74879.cd
49. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet Lond Engl. 2004;364(9429):141-148. doi:10.1016/S0140-6736(04)16626-9
50. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction. N Engl J Med. 2006;355(12):1210-1221. doi:10.1056/NEJMoa060186
51. Ge J, Li Y, Qian J, et al. Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). Heart Br Card Soc. 2006;92(12):1764-1767. doi:10.1136/hrt.2005.085431
52. Yousef M, Schannwell CM, Köstering M, Zeus T, Brehm M, Strauer BE. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol. 2009;53(24):2262-2269. doi:10.1016/j.jacc.2009.02.051
53. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012;(2):CD006536. doi:10.1002/14651858.CD006536.pub3
54. Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2014;(4):CD007888. doi:10.1002/14651858.CD007888.pub2
55. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110-2119. doi:10.1001/jama.2011.1670
56. Sürder D, Manka R, Moccetti T, et al. Effect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results. Circ Res. 2016;119(3):481-490. doi:10.1161/CIRCRESAHA.116.308639
57. Traverse JH, Henry TD, Pepine CJ, et al. TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. Circ Res. 2018;122(3):479-488. doi:10.1161/CIRCRESAHA.117.311466
58. Harrison DE, Astle CM, Lerner C. Number and continuous proliferative pattern of transplanted primitive immunohematopoietic stem cells. Proc Natl Acad Sci U S A. 1988;85(3):822-826. doi:10.1073/pnas.85.3.822
59. Bongiovanni D, Bassetti B, Gambini E, et al. The CD133+ cell as advanced medicinal product for myocardial and limb ischemia. Stem Cells Dev. 2014;23(20):2403-2421. doi:10.1089/scd.2014.0111
60. Tendera M, Wojakowski W, Ruzyłło W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009;30(11):1313-1321. doi:10.1093/eurheartj/ehp073
61. Mansour S, Roy DC, Bouchard V, et al. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Res. 2011;2011:385124. doi:10.1155/2011/385124
62. Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428-436. doi:10.1161/CIRCRESAHA.111.245993
63. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147. doi:10.1126/science.284.5411.143
64. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905
65. Roura S, Gálvez-Montón C, Mirabel C, Vives J, Bayes-Genis A. Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? Stem Cell Res Ther. 2017;8(1):238. doi:10.1186/s13287-017-0695-y
66. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277-2286. doi:10.1016/j.jacc.2009.06.055
67. Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion and Fibrotic Burden when Administered to Patients Undergoing Coronary Artery Bypass Grafting – The PROMETHEUS Trial. Circ Res. 2014;114(8):1302-1310. doi:10.1161/ circresaha.114.303180
68. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62-73. doi:10.1001/jama. 2013.282909
69. Florea V, Rieger AC, DiFede DL, et al. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circ Res. 2017;121(11):1279-1290. doi:10.1161/circresaha.117.311827
70. Perin EC, Borow KM, Henry TD, et al. Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure. JACC. 2023;81(9):849-863. doi:10.1016/j. jacc.2022.11.061
71. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet. 2004;363(9419):1439-1441. doi:10.1016/ S0140-6736(04)16104-7
72. Hare JM, DiFede DL, Rieger AC, et al. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017;69(5):526-537. doi:10.1016/j.jacc. 2016.11.009
73. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379. doi:10.1001/ jama.2012.25321
74. Jansen Of Lorkeers SJ, Eding JEC, Vesterinen HM, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res. 2015;116(1):80-86. doi:10.1161/CIRCRESAHA.116.304872
75. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810-834. doi:10.1161/CIRCRESAHA.113.300219
76. Zhang Y, Zhang Z, Gao F, Tse HF, Tergaonkar V, Lian Q. Paracrine regulation in mesenchymal stem cells: the role of Rap1. Cell Death Dis. 2015;6(10):e1932. doi:10.1038/cddis.2015.285
77. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-3506. doi:10.1182/blood-2007-02-069716
78. Yang J, Zhou W, Zheng W, et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology. 2007;107(1):17-29. doi:10.1159/000093609
79. Rezaie J, Rahbarghazi R, Pezeshki M, et al. Cardioprotective role of extracellular vesicles: A highlight on exosome beneficial effects in cardiovascular diseases. J Cell Physiol. 2019;234(12):21732-21745. doi:10.1002/jcp.28894
80. Baptista LS. Adipose stromal/stem cells in regenerative medicine: Potentials and limitations. World J Stem Cells. 2020;12(1):1-7. doi:10.4252/ wjsc.v12.i1.1
81. Cousin B, Casteilla L, Laharrague P, et al. Immuno-metabolism and adipose tissue: The key role of hematopoietic stem cells. Biochimie. 2016;124:21-26. doi:10.1016/j.biochi.2015.06.012
82. DelaRosa O, Sánchez-Correa B, Morgado S, et al. Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev. 2012;21(8):1333-1343. doi:10.1089/scd.2011.0139
83. Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First Experience in Humans Using Adipose Tissue–Derived Regenerative Cells in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. JACC. 2012;59(5):539-540. doi:10.1016/j.jacc.2011.09.065
84. Comella K, Parcero J, Bansal H, et al. Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy. J Transl Med. 2016;14(1):158. doi:10.1186/s12967-016-0918-5
85. Qayyum AA, Mathiasen AB, Helqvist S, et al. Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results. J Transl Med. 2019;17(1):360. doi:10.1186/s12967-019-2110-1
86. Qayyum AA, Frljak S, Juhl M, et al. Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study. ESC Heart Fail. 2024;11(6):3882-3891. doi:10.1002/ehf2.14925
87. Hsiao STF, Asgari A, Lokmic Z, et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 2012;21(12):2189-2203. doi:10.1089/scd.2011.0674
88. Acquistapace A, Bru T, Lesault PF, et al. Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer. Stem Cells Dayt Ohio. 2011;29(5):812-824. doi:10.1002/stem.632
89. Metzele R, Alt C, Bai X, et al. Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic contraction after fusion with neonatal rat cardiomyocytes. FASEB J Off Publ Fed Am Soc Exp Biol. 2011;25(3):830-839. doi:10.1096/fj.09-153221
90. Mori D, Miyagawa S, Kawamura T, et al. Mitochondrial Transfer Induced by Adipose-Derived Mesenchymal Stem Cell Transplantation Improves Cardiac Function in Rat Models of Ischemic Cardiomyopathy. Cell Transplant. 2023;32:9636 897221148457. doi:10.1177/09636897221148457
91. Che Y, Shimizu Y, Murohara T. Therapeutic Potential of Adipose-Derived Regenerative Cells for Ischemic Diseases. Cells. 2025;14(5):343. doi:10.3390/ cells14050343
92. Bui TVA, Hwang JW, Lee JH, Park HJ, Ban K. Challenges and Limitations of Strategies to Promote Therapeutic Potential of Human Mesenchymal Stem Cells for Cell-Based Cardiac Repair. Korean Circ J. 2021;51(2):97-113. doi:10.4070/kcj.2020.0518
93. Garcia JP, Avila FR, Torres RA, et al. Hypoxia-preconditioning of human adipose-derived stem cells enhances cellular proliferation and angiogenesis: A systematic review. J Clin Transl Res. 2022;8(1):61-70.
94. Abd Emami B, Mahmoudi E, Shokrgozar MA, et al. Mechanical and Chemical Predifferentiation of Mesenchymal Stem Cells Into Cardiomyocytes and Their Effectiveness on Acute Myocardial Infarction. Artif Organs. 2018;42(6):E114-E126. doi:10.1111/aor.13091
95. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let’s not overlook some essential precautions. Blood. 2006;109(8):3147-3151. doi:10.1182/blood-2006-03-013433
96. Mathur A, Fernández-Avilés F, Bartunek J, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. Eur Heart J. 2020;41(38):3702-3710. doi:10.1093/eurheartj/ehaa651
97. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329-2338. doi:10.1016/j.jacc.2013.02.071
98. Seyihoglu B, Orhan I, Okudur N, et al. 20 years of treating ischemic cardiomyopathy with mesenchymal stromal cells: a meta-analysis and systematic review. Cytotherapy. 2024;26(12):1443-1457. doi:10.1016/j.jcyt.2024.07.004
99. Abouzid MR, Umer AM, Jha SK, et al. Stem Cell Therapy for Myocardial Infarction and Heart Failure: A Comprehensive Systematic Review and Critical Analysis. Cureus. 2024;16(5):e59474. doi:10.7759/cureus.59474
100. Gyöngyösi M, Pokushalov E, Romanov A, et al. Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data. J Clin Med. 2022;11(11):3205. doi:10.3390/jcm11113205
101. Fu H, Chen Q. Mesenchymal stem cell therapy for heart failure: a meta-analysis. Herz. 2020;45(6): 557-563. doi:10.1007/s00059-018-4762-7
102. Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12(1):545. doi:10.1186/s13287-021-02609-x
103. Wuputra K, Ku CC, Wu DC, Lin YC, Saito S, Yokoyama KK. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Exp Clin Cancer Res. 2020;39(1):100. doi:10.1186/s13046-020-01584-0
104. Jeong JO, Han JW, Kim JM, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011;108(11):1340-1347. doi:10.1161/CIRCRESAHA.110.239848
105. Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells Dayt Ohio. 2006;24(4): 1095-1103. doi:10.1634/stemcells.2005-0403
106. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):1362-1369. doi:10.1182/blood-2006-12-063412
107. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557-563. doi:10.1038/nature06188
108. Ji SQ, Cao J, Zhang QY, Li YY, Yan YQ, Yu FX. Adipose tissue-derived stem cells promote pancreatic cancer cell proliferation and invasion. Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol. 2013;46(9):758-764. doi:10.1590/1414-431X20132907
109. Bruun K, Schermer E, Sivendra A, et al. Therapeutic applications of adipose-derived stem cells in cardiovascular disease. Am J Stem Cells. 2018;7(4):94-103.
110. Kastrup J, Haack-Sørensen M, Juhl M, et al. Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study. Stem Cells Transl Med. 2017;6(11):1963-1971. doi:10.1002/sctm.17-0040
111. Fliedner TM, Chao NJ, Bader JL, et al. Stem Cells, Multiorgan Failure in Radiation Emergency Medical Preparedness: A U.S./European Consultation Workshop. Stem Cells. 2009;27(5):1205-1211. doi:10.1002/stem.16
112. Ghosh S, Salvador-Culla B, Kotagiri A, et al. Acute Chemical Eye Injury and Limbal Stem Cell Deficiency—A Prospective Study in the United Kingdom. Cornea. 2019;38(1):8. doi:10.1097/ICO. 0000000000001739
2. Premer C, Schulman IH, Jackson JS. The role of mesenchymal stem/stromal cells in the acute clinical setting. Am J Emerg Med. 2021;46:572-578. doi:10.1016/j.ajem.2020.11.035
3. Assmus B, Dimmeler S, Zeiher AM. Cardiac Cell Therapy. Circ Res. 2015;116(8):1291-1292. doi:10.1161/CIRCRESAHA.115.306330
4. Öztürk S, Elçin AE, Koca A, Elçin YM. Therapeutic Applications of Stem Cells and Extracellular Vesicles in Emergency Care: Futuristic Perspectives. Stem Cell Rev Rep. 2021;17(2):390-410. doi:10.1007/s12015-020-10029-2
5. Ali SA, Mahmood Z, Mubarak Z, et al. Assessing the Potential Benefits of Stem Cell Therapy in Cardiac Regeneration for Patients With Ischemic Heart Disease. Cureus. 2025;17(1):e76770. doi:10.7759/cureus.76770
6. Marbán E. Breakthroughs in Cell Therapy for Heart Disease: Focus on Cardiosphere-Derived Cells. Mayo Clin Proc. 2014;89(6):850-858. doi:10.1016/j.mayocp.2014.02.014
7. Chepeleva EV. Cell Therapy in the Treatment of Coronary Heart Disease. Int J Mol Sci. 2023;24(23):16844. doi:10.3390/ijms242316844
8. Skrypnyk M. Current progress and limitations of research regarding the therapeutic use of adipose-derived stem cells: literature review. J Umm Al-Qura Univ Appl Sci. 2025;11(1):63-75. doi:10.1007/s43994-024-00147-9
9. Rheault-Henry M, White I, Grover D, Atoui R. Stem cell therapy for heart failure: Medical breakthrough, or dead end? World J Stem Cells. 2021;13(4):236-259. doi:10.4252/wjsc.v13.i4.236
10. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step. Circulation. 2006;114(4):339-352. doi:10.1161/ circulationaha.105.590653
11. Chakravarti AR, Pacelli S, Alam P, et al. Pre-Conditioning Stem Cells in a Biomimetic Environment for Enhanced Cardiac Tissue Repair: In Vitro and In Vivo Analysis. Cell Mol Bioeng. 2018;11(5):321-336. doi:10.1007/s12195-018-0543-x
12. Xue T, Cho HC, Akar FG, et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation. 2005;111(1):11-20. doi:10.1161/01.CIR.0000151313.18547.A2
13. Menasché P, Vanneaux V, Hagège A, et al. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2018;71(4):429-438. doi:10.1016/j.jacc.2017.11.047
14. Menasché P, Vanneaux V, Hagège A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. 2015;36(30):2011-2017. doi:10.1093/eurheartj/ehv189
15. Dhar D, Hsi-En Ho J. Stem cell research policies around the world. Yale J Biol Med. 2009;82(3):113-115.
16. Lin Q, Fu Q, Zhang Y, et al. Tumourigenesis in the infarcted rat heart is eliminated through differentiation and enrichment of the transplanted embryonic stem cells. Eur J Heart Fail. 2010;12(11):1179-1185. doi:10.1093/eurjhf/hfq144
17. Brizard CP, Elwood NJ, Kowalski R, et al. Safety and feasibility of adjunct autologous cord blood stem cell therapy during the Norwood heart operation. J Thorac Cardiovasc Surg. 2023;166(6):1746-1755. doi:10.1016/j.jtcvs.2023.07.035
18. Ahmed MM, Meece LE, Handberg EM, et al. Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recipients: Results of the uSTOP LVAD BLEED pilot study. JHLT Open. 2024;3:100037. doi:10.1016/j.jhlto.2023. 100037
19. Troyer DL, Weiss ML. Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells Dayt Ohio. 2008;26(3):591-599. doi:10.1634/ stemcells.2007-0439
20. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013;14(6):11692-11712. doi:10.3390/ijms140611692
21. Gao LR, Chen Y, Zhang NK, et al. Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Med. 2015;13:162. doi:10.1186/s12916-015-0399-z
22. Roura S, Bagó JR, Soler-Botija C, et al. Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in vivo. PloS One. 2012;7(11):e49447. doi:10.1371/journal.pone.0049447
23. Lim M, Wang W, Liang L, et al. Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction. Stem Cell Res Ther. 2018;9(1):129. doi:10.1186/s13287-018-0888-z
24. Correa A, Ottoboni GS, Senegaglia AC, et al. Expanded CD133+ Cells from Human Umbilical Cord Blood Improved Heart Function in Rats after Severe Myocardial Infarction. Stem Cells Int. 2018;2018:5412478. doi:10.1155/2018/5412478
25. Liu C, Kang LN, Chen F, et al. Immediate Intracoronary Delivery of Human Umbilical Cord Mesenchymal Stem Cells Reduces Myocardial Injury by Regulating the Inflammatory Process Through Cell-Cell Contact with T Lymphocytes. Stem Cells Dev. 2020;29(20):1331-1345. doi:10.1089/scd.2019.0264
26. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872. doi:10.1016/j.cell.2007.11.019
27. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. doi:10.1016/j.cell.2006.07.024
28. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-1920. doi:10.1126/science.1151526
29. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104(4):e30-41. doi:10.1161/CIRCRESAHA.108.192237
30. Blin G, Nury D, Stefanovic S, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest. 2010;120(4):1125-1139. doi:10.1172/ JCI40120
31. Dixit P, Katare R. Challenges in identifying the best source of stem cells for cardiac regeneration therapy. Stem Cell Res Ther. 2015;6(1):26. doi:10.1186/s13287-015-0010-8
32. Ahmed RPH, Ashraf M, Buccini S, Shujia J, Haider HK. Cardiac tumorigenic potential of induced pluripotent stem cells in an immunocompetent host with myocardial infarction. Regen Med. 2011;6(2):171-178. doi:10.2217/rme.10.103
33. Rais Y, Zviran A, Geula S, et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature. 2013;502(7469):65-70. doi:10.1038/natur e12587
34. Kirkeby A, Main H, Carpenter M. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell. 2025;32(1):10-37. doi:10.1016/j.stem.2024.12.005
35. Ortuño-Costela MDC, Cerrada V, García-López M, Gallardo ME. The Challenge of Bringing iPSCs to the Patient. Int J Mol Sci. 2019;20(24):6305. doi:10.3390/ijms20246305
36. He JQ, Vu DM, Hunt G, Chugh A, Bhatnagar A, Bolli R. Human cardiac stem cells isolated from atrial appendages stably express c-kit. PloS One. 2011;6(11):e27719. doi:10.1371/journal.pone.0027719
37. Madigan M, Atoui R. Therapeutic Use of Stem Cells for Myocardial Infarction. Bioeng Basel Switz. 2018;5(2):28. doi:10.3390/bioengineering5020028
38. Moccetti T, Leri A, Goichberg P, Rota M, Anversa P. A Novel Class of Human Cardiac Stem Cells. Cardiol Rev. 2015;23(4):189-200. doi:10.1097/CRD.0000 000000000064
39. Samanta A, Dawn B. Meta-Analysis of Preclinical Data Reveals Efficacy of Cardiac Stem Cell Therapy for Heart Repair. Circ Res. 2016;118(8):1186-1188. doi:10.1161/CIRCRESAHA.116.308620
40. Makkar RR, Kereiakes DJ, Aguirre F, et al. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2020;41(36):3451-3458. doi:10.1093/eurheartj/ehaa541
41. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110-122. doi:10.1016/j.jacc.2013.08.724
42. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329-2338. doi:10.1016/j.jacc.2013.02.071
43. Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38(9):648-660. doi:10.1093/ eurheartj/ehw543
44. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313-12318. doi:10.1073/pnas.2132126100
45. Micheu MM, Dorobantu M. Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction. World J Stem Cells. 2017;9(4):68-76. doi:10.4252/wjsc.v9.i4.68
46. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98(18):10344-10349. doi:10.1073/pnas.181177898
47. Nigro P, Bassetti B, Cavallotti L, Catto V, Carbucicchio C, Pompilio G. Cell therapy for heart disease after 15 years: Unmet expectations. Pharmacol Res. 2018;127:77-91. doi:10.1016/j. phrs.2017.02.015
48. Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009-3017. doi:10.1161/01.cir.0000043246.74879.cd
49. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet Lond Engl. 2004;364(9429):141-148. doi:10.1016/S0140-6736(04)16626-9
50. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction. N Engl J Med. 2006;355(12):1210-1221. doi:10.1056/NEJMoa060186
51. Ge J, Li Y, Qian J, et al. Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). Heart Br Card Soc. 2006;92(12):1764-1767. doi:10.1136/hrt.2005.085431
52. Yousef M, Schannwell CM, Köstering M, Zeus T, Brehm M, Strauer BE. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol. 2009;53(24):2262-2269. doi:10.1016/j.jacc.2009.02.051
53. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012;(2):CD006536. doi:10.1002/14651858.CD006536.pub3
54. Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2014;(4):CD007888. doi:10.1002/14651858.CD007888.pub2
55. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110-2119. doi:10.1001/jama.2011.1670
56. Sürder D, Manka R, Moccetti T, et al. Effect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results. Circ Res. 2016;119(3):481-490. doi:10.1161/CIRCRESAHA.116.308639
57. Traverse JH, Henry TD, Pepine CJ, et al. TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. Circ Res. 2018;122(3):479-488. doi:10.1161/CIRCRESAHA.117.311466
58. Harrison DE, Astle CM, Lerner C. Number and continuous proliferative pattern of transplanted primitive immunohematopoietic stem cells. Proc Natl Acad Sci U S A. 1988;85(3):822-826. doi:10.1073/pnas.85.3.822
59. Bongiovanni D, Bassetti B, Gambini E, et al. The CD133+ cell as advanced medicinal product for myocardial and limb ischemia. Stem Cells Dev. 2014;23(20):2403-2421. doi:10.1089/scd.2014.0111
60. Tendera M, Wojakowski W, Ruzyłło W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009;30(11):1313-1321. doi:10.1093/eurheartj/ehp073
61. Mansour S, Roy DC, Bouchard V, et al. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Res. 2011;2011:385124. doi:10.1155/2011/385124
62. Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428-436. doi:10.1161/CIRCRESAHA.111.245993
63. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147. doi:10.1126/science.284.5411.143
64. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905
65. Roura S, Gálvez-Montón C, Mirabel C, Vives J, Bayes-Genis A. Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? Stem Cell Res Ther. 2017;8(1):238. doi:10.1186/s13287-017-0695-y
66. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277-2286. doi:10.1016/j.jacc.2009.06.055
67. Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion and Fibrotic Burden when Administered to Patients Undergoing Coronary Artery Bypass Grafting – The PROMETHEUS Trial. Circ Res. 2014;114(8):1302-1310. doi:10.1161/ circresaha.114.303180
68. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62-73. doi:10.1001/jama. 2013.282909
69. Florea V, Rieger AC, DiFede DL, et al. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circ Res. 2017;121(11):1279-1290. doi:10.1161/circresaha.117.311827
70. Perin EC, Borow KM, Henry TD, et al. Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure. JACC. 2023;81(9):849-863. doi:10.1016/j. jacc.2022.11.061
71. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet. 2004;363(9419):1439-1441. doi:10.1016/ S0140-6736(04)16104-7
72. Hare JM, DiFede DL, Rieger AC, et al. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017;69(5):526-537. doi:10.1016/j.jacc. 2016.11.009
73. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379. doi:10.1001/ jama.2012.25321
74. Jansen Of Lorkeers SJ, Eding JEC, Vesterinen HM, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res. 2015;116(1):80-86. doi:10.1161/CIRCRESAHA.116.304872
75. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810-834. doi:10.1161/CIRCRESAHA.113.300219
76. Zhang Y, Zhang Z, Gao F, Tse HF, Tergaonkar V, Lian Q. Paracrine regulation in mesenchymal stem cells: the role of Rap1. Cell Death Dis. 2015;6(10):e1932. doi:10.1038/cddis.2015.285
77. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-3506. doi:10.1182/blood-2007-02-069716
78. Yang J, Zhou W, Zheng W, et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology. 2007;107(1):17-29. doi:10.1159/000093609
79. Rezaie J, Rahbarghazi R, Pezeshki M, et al. Cardioprotective role of extracellular vesicles: A highlight on exosome beneficial effects in cardiovascular diseases. J Cell Physiol. 2019;234(12):21732-21745. doi:10.1002/jcp.28894
80. Baptista LS. Adipose stromal/stem cells in regenerative medicine: Potentials and limitations. World J Stem Cells. 2020;12(1):1-7. doi:10.4252/ wjsc.v12.i1.1
81. Cousin B, Casteilla L, Laharrague P, et al. Immuno-metabolism and adipose tissue: The key role of hematopoietic stem cells. Biochimie. 2016;124:21-26. doi:10.1016/j.biochi.2015.06.012
82. DelaRosa O, Sánchez-Correa B, Morgado S, et al. Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev. 2012;21(8):1333-1343. doi:10.1089/scd.2011.0139
83. Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First Experience in Humans Using Adipose Tissue–Derived Regenerative Cells in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. JACC. 2012;59(5):539-540. doi:10.1016/j.jacc.2011.09.065
84. Comella K, Parcero J, Bansal H, et al. Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy. J Transl Med. 2016;14(1):158. doi:10.1186/s12967-016-0918-5
85. Qayyum AA, Mathiasen AB, Helqvist S, et al. Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results. J Transl Med. 2019;17(1):360. doi:10.1186/s12967-019-2110-1
86. Qayyum AA, Frljak S, Juhl M, et al. Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study. ESC Heart Fail. 2024;11(6):3882-3891. doi:10.1002/ehf2.14925
87. Hsiao STF, Asgari A, Lokmic Z, et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 2012;21(12):2189-2203. doi:10.1089/scd.2011.0674
88. Acquistapace A, Bru T, Lesault PF, et al. Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer. Stem Cells Dayt Ohio. 2011;29(5):812-824. doi:10.1002/stem.632
89. Metzele R, Alt C, Bai X, et al. Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic contraction after fusion with neonatal rat cardiomyocytes. FASEB J Off Publ Fed Am Soc Exp Biol. 2011;25(3):830-839. doi:10.1096/fj.09-153221
90. Mori D, Miyagawa S, Kawamura T, et al. Mitochondrial Transfer Induced by Adipose-Derived Mesenchymal Stem Cell Transplantation Improves Cardiac Function in Rat Models of Ischemic Cardiomyopathy. Cell Transplant. 2023;32:9636 897221148457. doi:10.1177/09636897221148457
91. Che Y, Shimizu Y, Murohara T. Therapeutic Potential of Adipose-Derived Regenerative Cells for Ischemic Diseases. Cells. 2025;14(5):343. doi:10.3390/ cells14050343
92. Bui TVA, Hwang JW, Lee JH, Park HJ, Ban K. Challenges and Limitations of Strategies to Promote Therapeutic Potential of Human Mesenchymal Stem Cells for Cell-Based Cardiac Repair. Korean Circ J. 2021;51(2):97-113. doi:10.4070/kcj.2020.0518
93. Garcia JP, Avila FR, Torres RA, et al. Hypoxia-preconditioning of human adipose-derived stem cells enhances cellular proliferation and angiogenesis: A systematic review. J Clin Transl Res. 2022;8(1):61-70.
94. Abd Emami B, Mahmoudi E, Shokrgozar MA, et al. Mechanical and Chemical Predifferentiation of Mesenchymal Stem Cells Into Cardiomyocytes and Their Effectiveness on Acute Myocardial Infarction. Artif Organs. 2018;42(6):E114-E126. doi:10.1111/aor.13091
95. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let’s not overlook some essential precautions. Blood. 2006;109(8):3147-3151. doi:10.1182/blood-2006-03-013433
96. Mathur A, Fernández-Avilés F, Bartunek J, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. Eur Heart J. 2020;41(38):3702-3710. doi:10.1093/eurheartj/ehaa651
97. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329-2338. doi:10.1016/j.jacc.2013.02.071
98. Seyihoglu B, Orhan I, Okudur N, et al. 20 years of treating ischemic cardiomyopathy with mesenchymal stromal cells: a meta-analysis and systematic review. Cytotherapy. 2024;26(12):1443-1457. doi:10.1016/j.jcyt.2024.07.004
99. Abouzid MR, Umer AM, Jha SK, et al. Stem Cell Therapy for Myocardial Infarction and Heart Failure: A Comprehensive Systematic Review and Critical Analysis. Cureus. 2024;16(5):e59474. doi:10.7759/cureus.59474
100. Gyöngyösi M, Pokushalov E, Romanov A, et al. Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data. J Clin Med. 2022;11(11):3205. doi:10.3390/jcm11113205
101. Fu H, Chen Q. Mesenchymal stem cell therapy for heart failure: a meta-analysis. Herz. 2020;45(6): 557-563. doi:10.1007/s00059-018-4762-7
102. Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12(1):545. doi:10.1186/s13287-021-02609-x
103. Wuputra K, Ku CC, Wu DC, Lin YC, Saito S, Yokoyama KK. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Exp Clin Cancer Res. 2020;39(1):100. doi:10.1186/s13046-020-01584-0
104. Jeong JO, Han JW, Kim JM, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011;108(11):1340-1347. doi:10.1161/CIRCRESAHA.110.239848
105. Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells Dayt Ohio. 2006;24(4): 1095-1103. doi:10.1634/stemcells.2005-0403
106. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):1362-1369. doi:10.1182/blood-2006-12-063412
107. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557-563. doi:10.1038/nature06188
108. Ji SQ, Cao J, Zhang QY, Li YY, Yan YQ, Yu FX. Adipose tissue-derived stem cells promote pancreatic cancer cell proliferation and invasion. Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol. 2013;46(9):758-764. doi:10.1590/1414-431X20132907
109. Bruun K, Schermer E, Sivendra A, et al. Therapeutic applications of adipose-derived stem cells in cardiovascular disease. Am J Stem Cells. 2018;7(4):94-103.
110. Kastrup J, Haack-Sørensen M, Juhl M, et al. Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study. Stem Cells Transl Med. 2017;6(11):1963-1971. doi:10.1002/sctm.17-0040
111. Fliedner TM, Chao NJ, Bader JL, et al. Stem Cells, Multiorgan Failure in Radiation Emergency Medical Preparedness: A U.S./European Consultation Workshop. Stem Cells. 2009;27(5):1205-1211. doi:10.1002/stem.16
112. Ghosh S, Salvador-Culla B, Kotagiri A, et al. Acute Chemical Eye Injury and Limbal Stem Cell Deficiency—A Prospective Study in the United Kingdom. Cornea. 2019;38(1):8. doi:10.1097/ICO. 0000000000001739